Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled, Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects With Mild Alzheimer's Disease and Impaired Glucose Tolerance

NCT03980730 is registered in ClinicalTrials.gov with vTv Therapeutics as lead sponsor.

NCT NCT03980730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03980730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled, Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects With Mild Alzheimer's Disease and Impaired Glucose Tolerance
Lead sponsor
vTv Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
June 27, 2019
Completion date
January 29, 2021
Enrollment
43 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease